Aldeyra Therapeutics, Inc.
- Open
- 2.13
- Day high
- 2.25
- Day low
- 2.10
- Prev close
- 2.13
- Volume
- 709K
- Mkt cap
- $133M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.2
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $418K over the last 3 months (1 open-market buy, 0 sales)
- 🏛Institutions mixed (13F)
Aldeyra Therapeutics, Inc. (ALDX) is a Healthcare company listed on NASDAQ. The stock is down 46% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 0 sales (SEC Form 4).
Aldeyra Therapeutics, Inc. (ALDX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ALDX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.13 | $-0.06 | +53.8% | — | — |
| Nov 5, 2025 | $-0.17 | $-0.13 | +23.5% | — | — |
| Aug 7, 2025 | $-0.21 | $-0.16 | +23.8% | — | — |
| May 14, 2025 | $-0.25 | $-0.17 | +32.0% | — | — |
| Feb 28, 2025 | $-0.25 | $-0.27 | -8.0% | $244526 | — |
| Nov 7, 2024 | $-0.25 | $-0.25 | +0.0% | — | — |
| Aug 1, 2024 | $-0.14 | $-0.28 | -100.0% | — | — |
| May 2, 2024 | $-0.08 | $-0.14 | -75.0% | — | — |
| Mar 7, 2024 | $-0.21 | $-0.08 | +61.9% | $392620 | -86.9% |
| Nov 3, 2023 | $-0.24 | $-0.14 | +41.7% | — | — |
| Aug 3, 2023 | $-0.31 | $-0.15 | +51.6% | — | — |
| May 4, 2023 | $-0.30 | $-0.27 | +10.0% | — | — |
ALDX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 11, 2026 | Walker Nealdirector | Grant | 70,000 | $1.72 |
| Jun 11, 2026 | Clark William Ddirector | Grant | 2,323 | $1.72 |
| Jun 11, 2026 | Clark William Ddirector | Grant | 70,000 | $1.72 |
| Jun 11, 2026 | Phillips Gary M.director | Grant | 4,977 | $1.72 |
| Jun 11, 2026 | Phillips Gary M.director | Grant | 6,636 | $1.72 |
| Jun 11, 2026 | Phillips Gary M.director | Grant | 70,000 | $1.72 |
| Jun 11, 2026 | DOUGLAS RICHARDdirector | Grant | 2,323 | $1.72 |
| Jun 11, 2026 | DOUGLAS RICHARDdirector | Grant | 19,909 | $1.72 |
| Jun 11, 2026 | DOUGLAS RICHARDdirector | Grant | 70,000 | $1.72 |
| Jun 11, 2026 | Miller-Rich Nancydirector | Grant | 3,318 | $1.72 |
| Jun 11, 2026 | Miller-Rich Nancydirector | Grant | 70,000 | $1.72 |
| Jun 11, 2026 | DEPTULA-HICKS DARLENE Mdirector | Grant | 9,756 | $1.72 |
| Jun 11, 2026 | DEPTULA-HICKS DARLENE Mdirector | Grant | 84,557 | $1.72 |
| Jun 11, 2026 | Bronstein Bendirector | Grant | 4,977 | $1.72 |
| Jun 11, 2026 | Bronstein Bendirector | Grant | 5,309 | $1.72 |
Source: ALDX SEC Form 4 filings, latest Jun 11, 2026. For informational purposes only — not investment advice.
See the full ALDX insider & 13F page →Aldeyra Therapeutics, Inc. company profile
Overview
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a biotechnology company founded in 2004 and based in Lexington, Massachusetts. Originally incorporated as Aldexa Therapeutics, the company changed its name to Aldeyra Therapeutics in March 2014, coinciding with its initial public offering. The company specializes in developing medicines for immune-mediated ocular and systemic diseases, with a focus on novel therapeutic approaches targeting reactive aldehyde species and other inflammatory pathways.
Business
Aldeyra Therapeutics operates in the biotechnology sector, specifically developing treatments for inflammatory diseases affecting the eyes and other organ systems. The company's core focus is on reactive aldehyde species (RASP) modulation, a novel therapeutic approach targeting harmful chemical compounds that contribute to inflammation and tissue damage. The company's lead product candidate is reproxalap, a topical eye drop designed to treat dry eye disease and allergic conjunctivitis. Dry eye disease is a common condition where the eyes don't produce enough tears or the tears evaporate too quickly, causing discomfort, vision problems, and potential damage to the eye surface. Allergic conjunctivitis occurs when the clear membrane covering the eye becomes inflamed due to allergens like pollen or dust mites. Aldeyra's pipeline includes several other drug candidates across different therapeutic areas. ADX-629 is an oral RASP modulator being tested for systemic inflammatory conditions including psoriasis (a skin condition causing scaly patches), asthma, and COVID-19 complications. ADX-2191 is a dihydrofolate reductase inhibitor - a type of drug that blocks a specific enzyme involved in cell division - being developed for rare eye conditions including proliferative vitreoretinopathy (scar tissue formation in the retina) and retinitis pigmentosa (a genetic disorder causing vision loss). The company also has licensing agreements, including one with Madrigal Pharmaceuticals for ADX-1612, which targets protein chaperones involved in inflammatory diseases. Protein chaperones are cellular "helper" proteins that assist in proper protein folding and function.
Revenue model
Aldeyra Therapeutics operates as a clinical-stage biotechnology company, meaning it currently generates minimal revenue and primarily relies on external funding to support its operations. The company's business model is based on developing pharmaceutical products through clinical trials with the ultimate goal of obtaining regulatory approval and commercializing these treatments. Currently, Aldeyra generates virtually no revenue, with only $244,526 reported in Q4 2024, likely from research collaborations or licensing agreements. The company's future revenue model will depend on successfully bringing its drug candidates to market through several potential pathways: direct commercialization of approved drugs, licensing agreements with larger pharmaceutical companies, or strategic partnerships for development and marketing. The company's profitability will be influenced by several key factors. Positive factors include the large market opportunity for dry eye treatments (estimated at several billion dollars globally), the potential for premium pricing given the novel mechanism of action, and the possibility of expanding RASP modulation technology to multiple therapeutic areas. However, margins face pressure from the high costs of clinical trials, regulatory approval processes, and the need to build commercial infrastructure for drug manufacturing and distribution. Competition from established pharmaceutical companies with existing dry eye treatments, the risk of clinical trial failures, and the substantial capital requirements for bringing drugs to market represent significant challenges. The company's cash burn rate of approximately $43 million annually means it must carefully manage resources while advancing multiple clinical programs simultaneously.
Competitive moat
Aldeyra Therapeutics' competitive moat is primarily built around its proprietary RASP modulation platform technology, which represents a novel approach to treating inflammatory diseases. This scientific differentiation provides some protection, as the company holds patents on its RASP modulator compounds and has developed specialized expertise in this therapeutic mechanism. However, the company's moat is relatively narrow and vulnerable to several competitive threats. The biotechnology industry is highly competitive, with large pharmaceutical companies possessing significantly greater resources for research, development, and commercialization. Established players in the dry eye market, such as Allergan (now part of AbbVie) with Restasis and Novartis with Xiidra, have strong market positions, extensive distribution networks, and substantial marketing capabilities. The company's intellectual property protection, while important, has limited duration and may face challenges from generic competitors once patents expire. Additionally, other biotechnology companies are pursuing alternative approaches to treating the same conditions, potentially with superior efficacy or safety profiles. Aldeyra's small size and limited commercial infrastructure represent significant disadvantages compared to established pharmaceutical companies. The company lacks the financial resources to conduct large-scale clinical trials simultaneously across multiple indications, potentially slowing its ability to establish market leadership. Furthermore, the regulatory approval process remains uncertain, and clinical trial failures could quickly erode any competitive advantages the company currently possesses.
Risks & safety
Aldeyra Therapeutics presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong liquidity but ongoing operational losses. **Cash Position and Burn Rate:** - Cash and short-term investments of $50.4 million as of Q1 2025, down from $54.5 million in Q4 2024 - Annual cash burn rate of approximately $43 million based on 2024 operations - Current cash runway of roughly 12-15 months at current burn rate - Strong current ratio of 6.39, indicating good short-term liquidity **Debt and Solvency:** - Low debt-to-equity ratio of 0.24, indicating minimal leverage - Total liabilities of $29.6 million against total assets of $93.2 million - No significant debt burden constraining operations **Valuation Metrics:** - Trading at negative P/E ratios due to losses, though recent price decline from $6.67 to $2.17 suggests potential value - Price-to-book ratio of 5.41, indicating premium valuation relative to book value - Graham net-net ratio above 1.0, suggesting assets exceed market value **Other Considerations:** - Pre-revenue stage with regulatory approval pending for lead candidates - High execution risk typical of clinical-stage biotechnology companies - Need for additional funding likely within 12-18 months
Recent development
Based on the available financial data and company description, Aldeyra Therapeutics has made significant strategic progress in advancing its drug development pipeline over recent years. The company has successfully advanced two drug candidates to the regulatory approval stage, with reproxalap for dry eye disease and ADX-2191 for primary vitreoretinal lymphoma both having FDA-accepted New Drug Applications (NDAs) as of 2022. The company has strategically expanded its RASP modulation platform beyond ocular diseases into systemic inflammatory conditions. This diversification strategy includes advancing ADX-629 through Phase II clinical trials for multiple indications including psoriasis, asthma, and COVID-19 complications. The company has also initiated clinical programs for additional rare diseases such as idiopathic nephrotic syndrome, Sjogren-Larsson syndrome, atopic dermatitis, chronic cough, and alcohol-associated hepatitis. Aldeyra has pursued strategic partnerships to expand its pipeline, including a licensing agreement with Madrigal Pharmaceuticals for ADX-1612, which targets protein chaperones for inflammatory diseases. This approach allows the company to leverage external expertise while maintaining focus on its core RASP modulation technology. The company has been preparing for potential commercialization of its lead candidates, developing different sales strategies for reproxalap (targeting optometrists and anterior segment ophthalmology) versus ADX-2191 (targeting retinal surgeons treating rare retinal diseases). However, the company has also indicated openness to partnership arrangements for commercialization, which could provide additional resources and market access.
ALDX company profile · for informational purposes only — not investment advice.
Track ALDX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free